Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocycline Dosing and Safety in Huntington's Disease
NCT00029874Phase 2Completed
- Sponsor
- Food and Drug Administration
- Start
- Sep 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of minocycline in Huntington's disease (HD) (3 arms), sponsored by Food and Drug Administration. Primary endpoints: Tolerability of Minocycline at 8 weeks and Safety Measures at 8 weeks. Started Sep 2001; status: completed.
02
Drugs
minocycline
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT00029874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00029874.